The Food and Drug Administration (FDA) accepted Pfizer’s application for an RSV vaccine for older adults, and is expected to make an approval decision by the spring. Pfizer in a statement on Wednesday ...

Pfizer is rushing to get its respiratory syncytial virus (RSV) vaccine out the door and into arms. A priority review from the FDA will certainly help. The pharma giant announced Wednesday that U.S.

NEW YORK (Reuters) - U.S. health regulators have not yet completed their review of a more protective form of Pfizer Inc's big-selling Prevnar vaccine that fights pneumonia and meningitis, the ...

Pfizer (NYSE:PFE) announced Tuesday that the FDA accepted its Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate PF-06928316 for priority review targeting ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

As Moderna’s COVID vaccine patent lawsuits wind their way through courts around the globe, Pfizer and BioNTech contend their rival is trying to monopolize the entire mRNA field. In the latest chapter ...

Thirteen essential drugs made at Pfizer’s Rocky Mount, N.C., facility — which was recently damaged by a tornado — have a vulnerability score higher than 90 percent, according to a July 26 report from ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus ...